Work

Multi-omic analysis and overall survival update of phase II TRIDENT study: Durvalumab plus olaparib in extensive-stage small-cell lung cancer (ES-SCLC).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.8101

Authors: Yuanyuan Zhao, Yan Huang, Hong Liu, Bijing Xiao, Li Zhang

Institutions: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410822750

Cites:

Cited by: 2

Related to: 10